Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8425774 | 0.85 | PDE4A (0.50) | ALDH1A1MAPTTSHRMAPK1PDE4A | |
| SCHEMBL7859196 | 0.81 | CA2 (0.52) | CA2CA12CA1CA7CA9 | |
| SCHEMBL5114151 | 0.81 | CA2 (0.52) | CA2CA12CA1CA7CA9 | |
| SCHEMBL30832957 | 0.81 | CA2 (0.52) | CA2CA12CA1CA7CA9 | |
| SCHEMBL3511079 | 0.79 | CYP1A1 (0.50) | CA2CA12CA1CA7CA9 | |
| SCHEMBL19423123 | 0.77 | CA2 (0.48) | CA2CA12CA1CA7CA9 | |
| SCHEMBL7859198 | 0.77 | CA2 (0.48) | CA2CA12CA1CA7CA9 | |
| SCHEMBL5044907 | 0.77 | CA2 (0.48) | CA2CA12CA1CA7CA9 | |
| SCHEMBL6335640 | 0.77 | CA2 (0.48) | CA2CA12CA1CA7CA9 | |
| SCHEMBL10945772 | 0.77 | ALDH1A1 (0.47) | CA2CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-5942641-A | TREATMENT OF ALZHEIMER'S DISEASE, NERVOUS SYSTEM DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-24 | — | — | US | disclosed |
| EP-0655992-B1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMA CO LTD (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0791570-A1 | Fluorenone derivatives, process for preparing the same and central or peripheral nerve degeneration repair and protective agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-27 | — | — | EP | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| EP-0655992-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-07 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| WO-1995000468-A1 | FLUORENONE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CENTRAL OR PERIPHERAL NERVE DEGENERATION REPAIR AND PROTECTIVE AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286169-A1 | Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds | TST, UMPS, UROD | CA2 4417/4885CA12 4265/4885CA1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.